BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
Number Citing Articles
1 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Geethangili M, Lin CW, Mersmann HJ, Ding ST. Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK/NF-κB Signaling Pathway. Int J Mol Sci 2021;22:10062. [PMID: 34576229 DOI: 10.3390/ijms221810062] [Reference Citation Analysis]
3 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
4 Saha MR, Dey P. Pharmacological benefits of Acacia against metabolic diseases: intestinal-level bioactivities and favorable modulation of gut microbiota. Arch Physiol Biochem 2021;:1-17. [PMID: 34411504 DOI: 10.1080/13813455.2021.1966475] [Reference Citation Analysis]
5 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
6 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Reference Citation Analysis]
7 Hadefi A, Verset L, Pezzullo M, Rosewick N, Degré D, Gustot T, Moreno C, Devière J, Trépo E. Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. Endosc Int Open 2021;9:E1792-800. [PMID: 34790547 DOI: 10.1055/a-1550-7668] [Reference Citation Analysis]
8 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022; 28(3): 310-331 [DOI: 10.3748/wjg.v28.i3.310] [Reference Citation Analysis]
9 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Reference Citation Analysis]
10 Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Reference Citation Analysis]
12 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2021:S0168-8278(21)02026-2. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Reference Citation Analysis]
13 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
14 Yong JN, Lim WH, Ng CH, Tan DJH, Xiao J, Tay PWL, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Tan EXX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01226-X. [PMID: 34801743 DOI: 10.1016/j.cgh.2021.11.014] [Reference Citation Analysis]
15 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
16 Yu Y, He C, Tan S, Huang M, Guo Y, Li M, Zhang Q, Amantini C. MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPKα. Analytical Cellular Pathology 2021;2021:1-13. [DOI: 10.1155/2021/4853355] [Reference Citation Analysis]
17 Thibaut R, Gage MC, Pineda-Torra I, Chabrier G, Venteclef N, Alzaid F. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J 2021. [PMID: 33860630 DOI: 10.1111/febs.15877] [Reference Citation Analysis]
18 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
19 Da Fonseca LG, Forner A. Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma-ready for their use? Aliment Pharmacol Ther 2021;54:850-1. [PMID: 34425013 DOI: 10.1111/apt.16556] [Reference Citation Analysis]
20 Goto RL, Tablas MB, Prata GB, Espírito Santo SG, Fernandes AAH, Cogliati B, Barbisan LF, Romualdo GR. Vitamin D3 supplementation alleviates chemically-induced cirrhosis-associated hepatocarcinogenesis. J Steroid Biochem Mol Biol 2022;215:106022. [PMID: 34774723 DOI: 10.1016/j.jsbmb.2021.106022] [Reference Citation Analysis]
21 Francque S. The Liver and the Cardiovascular System: Two of a Kind? J Am Heart Assoc 2021;10:e020286. [PMID: 33847140 DOI: 10.1161/JAHA.121.020286] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]
23 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Santos-Sánchez G, Cruz-Chamorro I, Álvarez-Ríos AI, Fernández-Santos JM, Vázquez-Román MV, Rodríguez-Ortiz B, Álvarez-Sánchez N, Álvarez-López AI, Millán-Linares MDC, Millán F, Pedroche J, Fernández-Pachón MS, Lardone PJ, Guerrero JM, Bejarano I, Carrillo-Vico A. Lupinus angustifolius Protein Hydrolysates Reduce Abdominal Adiposity and Ameliorate Metabolic Associated Fatty Liver Disease (MAFLD) in Western Diet Fed-ApoE-/- Mice. Antioxidants (Basel) 2021;10:1222. [PMID: 34439470 DOI: 10.3390/antiox10081222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Xin X, Cheng C, Bei-Yu C, Hong-Shan L, Hua-Jie T, Xin W, Zi-Ming A, Qin-Mei S, Yi-Yang H, Qin F. Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity. Front Nutr 2021;8:784354. [PMID: 34881283 DOI: 10.3389/fnut.2021.784354] [Reference Citation Analysis]
26 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wu JT, He BW, Cao JL, Yan JB, Chen ZY. Involvement of STING signaling pathway in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(24): 1396-1401 [DOI: 10.11569/wcjd.v29.i24.1396] [Reference Citation Analysis]
28 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
29 Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit 2021;27:e933860. [PMID: 34248137 DOI: 10.12659/MSM.933860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Yang M, Khoukaz L, Qi X, Kimchi ET, Staveley-O'Carroll KF, Li G. Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. Biomedicines 2021;9:1893. [PMID: 34944709 DOI: 10.3390/biomedicines9121893] [Reference Citation Analysis]
31 Bévant K, Desoteux M, Abdel Wahab AHA, Abdel Wahab SA, Metwally AM, Coulouarn C. DNA Methylation of TGFβ Target Genes: Epigenetic Control of TGFβ Functional Duality in Liver Cancer. Cells 2021;10:2207. [PMID: 34571856 DOI: 10.3390/cells10092207] [Reference Citation Analysis]
32 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Reference Citation Analysis]
33 Liu PS. Editorial Comment: Is Quantitative CT Fat Fraction Ready For Prime Time? AJR Am J Roentgenol 2021. [PMID: 34910544 DOI: 10.2214/AJR.21.27184] [Reference Citation Analysis]
34 Simoni-Nieves A, Salas-Silva S, Chávez-Rodríguez L, Escobedo-Calvario A, Desoteux M, Bucio L, Souza V, Miranda-Labra RU, Muñoz-Espinosa LE, Coulouarn C, Gutiérrez-Ruiz MC, Marquardt JU, Gomez-Quiroz LE. The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis. Cancers (Basel) 2021;13:1721. [PMID: 33917315 DOI: 10.3390/cancers13071721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. [PMID: 34118091 DOI: 10.1111/joim.13343] [Reference Citation Analysis]
36 Xu Y, Zhang M, Zhang Q, Yu X, Sun Z, He Y, Guo W. Role of Main RNA Methylation in Hepatocellular Carcinoma: N6-Methyladenosine, 5-Methylcytosine, and N1-Methyladenosine. Front Cell Dev Biol 2021;9:767668. [PMID: 34917614 DOI: 10.3389/fcell.2021.767668] [Reference Citation Analysis]
37 Li J, Qi J, Tang Y, Liu H, Zhou K, Dai Z, Yuan L, Sun C. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis. J Nanobiotechnology 2021;19:363. [PMID: 34789275 DOI: 10.1186/s12951-021-01108-8] [Reference Citation Analysis]
38 De Vincentis A, Tavaglione F, Spagnuolo R, Pujia R, Tuccinardi D, Mascianà G, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes (Lond) 2021. [PMID: 34750514 DOI: 10.1038/s41366-021-01015-w] [Reference Citation Analysis]
39 Gao F, He Q, Li G, Huang OY, Tang LJ, Wang XD, Targher G, Byrne CD, Luo JW, Zheng MH. A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. Liver Int 2021. [PMID: 34564946 DOI: 10.1111/liv.15064] [Reference Citation Analysis]
40 Albano E, Sutti S. The paradox role of cytotoxic T-lymphocytes in NAFLD-associated hepatocellular carcinoma. Hepatobiliary Surg Nutr 2021;10:705-7. [PMID: 34760980 DOI: 10.21037/hbsn-21-243] [Reference Citation Analysis]
41 Li X, Hong J, Wang Y, Pei M, Wang L, Gong Z. Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD. Front Mol Biosci 2021;8:733507. [PMID: 34660695 DOI: 10.3389/fmolb.2021.733507] [Reference Citation Analysis]
42 Yang C, Wan M, Xu D, Pan D, Xia H, Yang L, Sun G. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. Int J Mol Sci 2021;22:10858. [PMID: 34639207 DOI: 10.3390/ijms221910858] [Reference Citation Analysis]
43 Yang H, Arif M, Yuan M, Li X, Shong K, Türkez H, Nielsen J, Uhlén M, Borén J, Zhang C, Mardinoglu A. A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic fatty liver disease. iScience 2021;24:103222. [PMID: 34712920 DOI: 10.1016/j.isci.2021.103222] [Reference Citation Analysis]
44 Chao X, Wang S, Hlobik M, Ballabio A, Ni HM, Ding WX. Loss of Hepatic Transcription Factor EB Attenuates Alcohol-Associated Liver Carcinogenesis. Am J Pathol 2021:S0002-9440(21)00442-9. [PMID: 34717896 DOI: 10.1016/j.ajpath.2021.10.004] [Reference Citation Analysis]
45 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
46 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Lim MS, Goh GB, Chang JP, Low JK, Shelat VG, Huey TC, Dan YY, Kow A, Shridhar I, Tan PS, Junnarkar SP, Tan CK. A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade. JGH Open 2021;5:1015-8. [PMID: 34584969 DOI: 10.1002/jgh3.12624] [Reference Citation Analysis]
48 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
49 Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:2305. [PMID: 34064999 DOI: 10.3390/cancers13102305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Kudo M. Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma? Liver Cancer 2021;10:289-95. [PMID: 34414117 DOI: 10.1159/000517841] [Reference Citation Analysis]
51 Wang X, Zeldin S, Shi H, Zhu C, Saito Y, Corey KE, Osganian SA, Remotti HE, Verna EC, Pajvani UB, Schwabe RF, Tabas I. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis. J Hepatol 2021:S0168-8278(21)02242-X. [PMID: 34902531 DOI: 10.1016/j.jhep.2021.11.031] [Reference Citation Analysis]
52 Jang TY, Huang CF, Yeh ML, Huang CI, Dai CY, Tsai PC, Hsu PY, Wei YJ, Hou NJ, Liang PC, Lin YH, Wang CW, Hsieh MY, Lin ZY, Huang JF, Yu ML, Chuang WL. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. Kaohsiung J Med Sci 2021. [PMID: 34786828 DOI: 10.1002/kjm2.12474] [Reference Citation Analysis]
53 Cholankeril G, Kanwal F. NAFLD and HCC: Time to Bridge the Gap. Hepatology 2021. [PMID: 34164841 DOI: 10.1002/hep.32025] [Reference Citation Analysis]
54 Yu Y, Tian T, Tan S, Wu P, Guo Y, Li M, Huang M. MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice. Bioengineered 2022;13:2927-42. [PMID: 35038955 DOI: 10.1080/21655979.2021.2017698] [Reference Citation Analysis]
55 Lee JS, Sinn DH, Park SY, Shin HJ, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Oh JH, Lee JI, Kim SU. Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:4567. [PMID: 34572795 DOI: 10.3390/cancers13184567] [Reference Citation Analysis]
56 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021;9:1524. [PMID: 34829753 DOI: 10.3390/biomedicines9111524] [Reference Citation Analysis]
57 Yuan P, Qi X, Song A, Ma M, Zhang X, Lu C, Bian M, Lian N, He J, Zheng S, Jin H. LncRNA MAYA promotes iron overload and hepatocyte senescence through inhibition of YAP in non-alcoholic fatty liver disease. J Cell Mol Med 2021;25:7354-66. [PMID: 34190396 DOI: 10.1111/jcmm.16764] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Delgado ME, Cárdenas BI, Farran N, Fernandez M. Metabolic Reprogramming of Liver Fibrosis. Cells 2021;10:3604. [PMID: 34944111 DOI: 10.3390/cells10123604] [Reference Citation Analysis]
59 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
60 Wu C, Zhou Y, Wang M, Dai G, Liu X, Lai L, Tang S. Bioinformatics Analysis Explores Potential Hub Genes in Nonalcoholic Fatty Liver Disease. Front Genet 2021;12:772487. [PMID: 34777484 DOI: 10.3389/fgene.2021.772487] [Reference Citation Analysis]
61 Moustakas II, Katsarou A, Legaki AI, Pyrina I, Ntostoglou K, Papatheodoridi AM, Gercken B, Pateras IS, Gorgoulis VG, Koutsilieris M, Chavakis T, Chatzigeorgiou A. Hepatic Senescence Accompanies the Development of NAFLD in Non-Aged Mice Independently of Obesity. Int J Mol Sci 2021;22:3446. [PMID: 33810566 DOI: 10.3390/ijms22073446] [Reference Citation Analysis]
62 Della Torre S. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. Cells 2021;10:2502. [PMID: 34572151 DOI: 10.3390/cells10092502] [Reference Citation Analysis]
63 Nasereldin DS, White LJ, Hodge DO, Roberts LR, Patel T, Antwi SO. Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. Dig Liver Dis 2021:S1590-8658(21)00889-6. [PMID: 34953761 DOI: 10.1016/j.dld.2021.12.002] [Reference Citation Analysis]
64 Mass Sanchez PB, Krizanac M, Weiskirchen R, Asimakopoulos A. Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights. Int J Mol Sci 2021;22:5284. [PMID: 34067931 DOI: 10.3390/ijms22105284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Le TNH, Choi HJ, Jun HS. Ethanol Extract of Liriope platyphylla Root Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice via Regulation of Lipogenesis and Lipid Uptake. Nutrients 2021;13:3338. [PMID: 34684339 DOI: 10.3390/nu13103338] [Reference Citation Analysis]
66 Topel H, Bağırsakçı E, Yılmaz Y, Güneş A, Bağcı G, Çömez D, Kahraman E, Korhan P, Atabey N. High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells. Sci Rep 2021;11:11376. [PMID: 34059694 DOI: 10.1038/s41598-021-89765-5] [Reference Citation Analysis]
67 Zhu LR, Ni WJ, Cai M, Dai WT, Zhou H. Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies. Front Cell Dev Biol 2021;9:777007. [PMID: 34778277 DOI: 10.3389/fcell.2021.777007] [Reference Citation Analysis]
68 Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 2021;54:880-9. [PMID: 34435378 DOI: 10.1111/apt.16583] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Chapman NM, Chi H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity 2022;55:14-30. [PMID: 35021054 DOI: 10.1016/j.immuni.2021.12.012] [Reference Citation Analysis]
70 Mahata T, Sengar AS, Basak M, Das K, Pramanick A, Verma SK, Singh PK, Biswas S, Sarkar S, Saha S, Chatterjee S, Das M, Stewart A, Maity B. Hepatic Regulator of G Protein Signaling 6 (RGS6) drives non-alcoholic fatty liver disease by promoting oxidative stress and ATM-dependent cell death. Redox Biol 2021;46:102105. [PMID: 34534913 DOI: 10.1016/j.redox.2021.102105] [Reference Citation Analysis]
71 Mallet V, Parlati L, Martinino A, Scarano Pereira JP, Navas Jimenez C, Sakka M, Bouam S, Retbi A, Krasteva D, Meritet JF, Schwarzinger M, Thabut D, Rufat P, Bonnefont-Rousselot D, Sogni P, Pol S, Tsochatzis E; Demosthenes research group. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J Hepatol 2021:S0168-8278(21)02092-4. [PMID: 34606913 DOI: 10.1016/j.jhep.2021.09.030] [Reference Citation Analysis]
72 Qian H, Chao X, Williams J, Fulte S, Li T, Yang L, Ding WX. Autophagy in liver diseases: A review. Mol Aspects Med 2021;:100973. [PMID: 34120768 DOI: 10.1016/j.mam.2021.100973] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
73 Kabarra K, Golabi P, Younossi ZM. Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect 2021;10:R240-7. [PMID: 34486981 DOI: 10.1530/EC-21-0048] [Reference Citation Analysis]
74 Xu H, Wang L. The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. Front Mol Biosci 2021;8:792667. [PMID: 34901163 DOI: 10.3389/fmolb.2021.792667] [Reference Citation Analysis]
75 Huang L, Zeng X, Li B, Wang C, Zhou M, Lang H, Yi L, Mi M. Dihydromyricetin attenuates palmitic acid-induced oxidative stress by promoting autophagy via SIRT3-ATG4B signaling in hepatocytes. Nutr Metab (Lond) 2021;18:83. [PMID: 34503544 DOI: 10.1186/s12986-021-00612-w] [Reference Citation Analysis]
76 Kumari B, Kumar R, Sharma S, Banerjee A, Kumar V, Kumar P, Chaudhary N, Kumar S, Raj K. Diagnostic Accuracy of FIB-4 and FIB-5 Scores as Compared to Fibroscan for Assessment of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease. Cureus 2021;13:e17622. [PMID: 34646672 DOI: 10.7759/cureus.17622] [Reference Citation Analysis]
77 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Reference Citation Analysis]
78 Guo B, Zhou Y, Liu B, He Y, Chen F, Cheng KW. Lipid-Lowering Bioactivity of Microalga Nitzschia laevis Extract Containing Fucoxanthin in Murine Model and Carcinomic Hepatocytes. Pharmaceuticals (Basel) 2021;14:1004. [PMID: 34681228 DOI: 10.3390/ph14101004] [Reference Citation Analysis]
79 Liu Z, Suo C, Zhao R, Yuan H, Jin L, Zhang T, Chen X. Genetic predisposition, lifestyle risk, and obesity associate with the progression of nonalcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00379-0. [PMID: 34348882 DOI: 10.1016/j.dld.2021.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 2021. [PMID: 34129272 DOI: 10.1111/hepr.13685] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
81 Sugasawa T, Ono S, Yonamine M, Fujita SI, Matsumoto Y, Aoki K, Nakano T, Tamai S, Yoshida Y, Kawakami Y, Takekoshi K. One Week of CDAHFD Induces Steatohepatitis and Mitochondrial Dysfunction with Oxidative Stress in Liver. Int J Mol Sci 2021;22:5851. [PMID: 34072586 DOI: 10.3390/ijms22115851] [Reference Citation Analysis]
82 Zhai R, Feng L, Zhang Y, Liu W, Li S, Hu Z. Combined Transcriptomic and Lipidomic Analysis Reveals Dysregulated Genes Expression and Lipid Metabolism Profiles in the Early Stage of Fatty Liver Disease in Rats. Front Nutr 2021;8:733197. [PMID: 34604283 DOI: 10.3389/fnut.2021.733197] [Reference Citation Analysis]
83 Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2021:S0168-8278(21)00326-3. [PMID: 33992698 DOI: 10.1016/j.jhep.2021.04.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Chen YC, Chen RJ, Peng SY, Yu WCY, Chang VH. Therapeutic Targeting of Nonalcoholic Fatty Liver Disease by Downregulating SREBP-1C Expression via AMPK-KLF10 Axis. Front Mol Biosci 2021;8:751938. [PMID: 34869587 DOI: 10.3389/fmolb.2021.751938] [Reference Citation Analysis]
85 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
86 Hirsova P, Bamidele AO, Wang H, Povero D, Revelo XS. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Front Endocrinol (Lausanne) 2021;12:760860. [PMID: 34777255 DOI: 10.3389/fendo.2021.760860] [Reference Citation Analysis]
87 Liu X, Shen H, Chen M, Shao J. Clinical relevance of environmental manganese exposure with liver stiffness and steatosis detected by transient elastography in adults. Environ Sci Pollut Res Int 2021. [PMID: 34651275 DOI: 10.1007/s11356-021-17012-5] [Reference Citation Analysis]
88 Tan J, Che Y, Liu Y, Hu J, Wang W, Hu L, Zhou Q, Wang H, Li J. CELSR2 deficiency suppresses lipid accumulation in hepatocyte by impairing the UPR and elevating ROS level. FASEB J 2021;35:e21908. [PMID: 34478580 DOI: 10.1096/fj.202100786RR] [Reference Citation Analysis]
89 Cao Y, Deng Y, Wang J, Zhao H, Zhang J, Xie W. The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. Ther Adv Chronic Dis 2021;12:20406223211048649. [PMID: 34777740 DOI: 10.1177/20406223211048649] [Reference Citation Analysis]
90 Cierpka R, Weiskirchen R, Asimakopoulos A. Perilipin 5 Ameliorates Hepatic Stellate Cell Activation via SMAD2/3 and SNAIL Signaling Pathways and Suppresses STAT3 Activation. Cells 2021;10:2184. [PMID: 34571833 DOI: 10.3390/cells10092184] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Yang H, Mayneris-Perxachs J, Boqué N, Del Bas JM, Arola L, Yuan M, Türkez H, Uhlén M, Borén J, Zhang C, Mardinoglu A, Caimari A. Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet. Biomedicines 2021;9:1440. [PMID: 34680557 DOI: 10.3390/biomedicines9101440] [Reference Citation Analysis]
92 Wang YL, Wu J, Li RX, Sun YT, Ma YJ, Zhao CY, Zou J, Zhang YY, Sun XD. A double-edged sword: The Kelch-like ECH-associated protein 1-nuclear factor erythroid-derived 2-related factor 2-antioxidant response element pathway targeted pharmacological modulation in nonalcoholic fatty liver disease. Curr Opin Pharmacol 2021;60:281-90. [PMID: 34500407 DOI: 10.1016/j.coph.2021.07.021] [Reference Citation Analysis]
93 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2 decades: the NAGALA study. BMC Gastroenterol 2021;21:223. [PMID: 34001028 DOI: 10.1186/s12876-021-01809-2] [Reference Citation Analysis]
94 Vogt G. Synthesis of digestive enzymes, food processing, and nutrient absorption in decapod crustaceans: a comparison to the mammalian model of digestion. Zoology (Jena) 2021;147:125945. [PMID: 34217027 DOI: 10.1016/j.zool.2021.125945] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, Jean-Charles G. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021;13:e17321. [PMID: 34557367 DOI: 10.7759/cureus.17321] [Reference Citation Analysis]
96 Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer 2021;162:76-98. [PMID: 34954439 DOI: 10.1016/j.ejca.2021.11.024] [Reference Citation Analysis]
97 Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells 2021;10:2034. [PMID: 34440803 DOI: 10.3390/cells10082034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Shatoor AS, Al Humayed S, Almohiy HM. Astaxanthin attenuates hepatic steatosis in high-fat diet-fed rats by suppressing microRNA-21 via transactivation of nuclear factor erythroid 2-related factor 2. J Physiol Biochem 2021. [PMID: 34651285 DOI: 10.1007/s13105-021-00850-9] [Reference Citation Analysis]